For security purposes
FOR SECURITY PURPOSES - because Internet Explorer is no longer supported by Microsoft, we suggest that you interact with our secure site through one of our supported browsers - Google Chrome, Firefox, or MS Edge. If you continue to use this website with Internet Explorer you do so at your own risk and you may encounter problems.
search
Documents
Enantiomeric Purity Analysis of the Drug Product Atorvastatin on Lux Amylose-1 According to the USP Monograph 2263 (TN-1192)
In this technical note, we report the enantiomeric separation between Atorvastatin and related compound E (enantiomer of Atorvastatin) using the polysaccharide-based chiral stationary phase Lux Amylose-1 (L51 USP column) according to United States Pharmacopeia monograph 2263.

Enantiomeric Purity Analysis of the Drug Product Atorvastatin on Lux Amylose-1 According to the USP Monograph 2263 (TN-1192)

In this technical note, we report the enantiomeric separation between Atorvastatin and related compound E (enantiomer of Atorvastatin) using the polysaccharide-based chiral stationary phase Lux Amylose-1 (L51 USP column) according to United States Pharmacopeia monograph 2263.
Document Type:
Technical Notes
Target Industries:
Pharmaceutical
Techniques:
HPLC
Brands:
Lux
Separation Modes:
Chiral
Phases:
Lux Amylose-1
save_alt Download
favorite_border
Phenomenex logo
Phenomenex is a technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers worldwide.
CONNECT WITH US

PRODUCTS AND SERVICES

Products

Techniques

Industries

Quick Order

SUPPORT 

Product/Method Support

Product Troubleshooting

Contact Us

CQA / CofA


OUR COMPANY

About Phenomenex

News

Blog

Danaher Life Sciences


Terms and Conditions Privacy Statement Quality Policy Terms of Use Trademarks CA Supply Chains Act CA Consumer Privacy Act Cookie Policy Impressum © 2023 Phenomenex Inc. All rights reserved.